|
Our researchers work at the forefront of innovative research and clinical trials, with more than $4 million in funded research.
Clinical trials are the foundation of our research. These important studies test the effectiveness of new medical approaches and treatments. Each study answers specific questions and tries to find better ways to prevent, screen for, diagnose and treat disease.
As a study participant, you will directly help us understand a specific disease better, which may lead to important advances in science, medicine and technology.
The department is currently enrolling participants for the following studies:
Phase II Study of Decitabine in Patients with Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine
STUDY SET UP: To determine if decitabine can restore radioiodine uptake in metastatic lesions of papillary thyroid cancer or follicular thyroid cancer that are undetectable by low-dose radioiodine scanning. Decitabine is an investigational drug and has not been approved by the FDA.
www.cancer.gov/clinicialtrials/MDA-2003-0308
Principal Investigator: David Steward, MD
Status: Ongoing, no patients enrolled to date
The Advance Trial: Tongue Advancement for Obstructive Sleep Apnea
STUDY SET UP: To test the effectiveness, performance and safety of the Advance System in treating obstructive sleep apnea. The Advance System is a surgical treatment that opens up the airway by moving the base of the tongue forward with a small device implanted inside the mandible. The region behind the tongue can collapse during obstructive sleep apnea. Moving the tongue forward can keep the tongue from blocking or reducing the airway.
www.aspiremedical.com
Principal Investigator: David Steward, MD
Status: Ongoing
An International Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA) versus Placebo in Subjects with Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
STUDY SET UP: To demonstrate an improvement in progression-free survival with ZD6474 as compared to placebo in subjects with unresectable locally advanced or metastatic medullary thyroid cancer. ZD6474 is an investigational drug taken orally once daily to inhibit tumor growth.
www.astrazenecaclinicaltrials.com
Principal Investigator: David Steward, MD
Status: Enrollment Satisfied, Ongoing
|
